- Free from Publisher C Triplitt, L Glass, Y Miyazaki, E Wajcberg, A … - Diabetes care, 2006 - Am Diabetes Assoc RESULTS—A1C and FPG decreased similarly in the glargine insulin (9.1 ± 0.4 to
7.6 ± 0.3% and 212 ± 14 to 139 ± 5 mg/dl, respectively, both P < 0.0001) and
rosiglitazone (9.4 ± 0.3 to 7.6 ± 0.4% and 223 ± 14 to 160 ± 19 mg/dl, ... Cited by 9 - Related articles - BL Direct - All 6 versions
P Curtis Triplitt, L Glass, Y Miyazaki, E … - medscape.com No previous study has examined the mechanisms by which addition of a
thiazolidinedione versus bedtime insulin improves glycemic control. Fasting
hyperglycemia in type 2 diabetes results from hepatic insulin resistance ... Related articles - All 3 versions
GTC Ko, PCC Tsang, HPS Wai, ECY Kan, … - Advances in therapy, 2006 - Springer This study was conducted to evaluate the efficacy and tolerability of
rosiglitazone in the treatment of patients with secondary oral antidiabetic drug
(OAD) failure and to directly compare its use with bedtime insulin. A total ... Cited by 7 - Related articles - BL Direct - All 4 versions
[CITATION] Health-related quality of life and costs of receiving add-on therapy with insulin glargine or …
LR Reynolds, FJ Kingsley, DG Karounos, LR … - Diabetes research and clinical practice, 2007 - Elsevier Forty subjects with type 2 diabetes and inadequate glycemic control on
sulfonylurea and metformin therapy received 24 weeks of add-on therapy with
either RSG 4 mg daily or IG 10 units daily. Subjects on RSG with fasting ... Cited by 10 - Related articles - All 10 versions
I Scott, P Greenberg, P Poole, D Campbell - Internal Medicine Journal, 2006 - pt.wkhealth.com This is the second in a series of articles emphasizing the cautions in the
interpretation of health-care studies. Systematic reviews are presented as
comprehensive, unbiased summaries of evidence and are often referred to by ... Cited by 5 - Related articles - All 4 versions
GA Nichols, CM Alexander, CJ Girman, SJ … - Endocrine Practice, 2007 - AACE Much of what is known about the long-term success of sulfonylurea (SU) therapy
in achieving and maintaining glycemic control is based on data obtained from
clinical trials or from older observational reports (1,2). The SU class of ... Cited by 9 - Related articles - BL Direct - All 8 versions
MB Davidson - Current Opinion in Endocrinology, Diabetes and …, 2009 - journals.lww.com Introduction There is an increasing chorus of people recommending insulin as
'early' treatment of type 2 diabetes in both print [1 ] and at national meetings
[2]. A subtext of this recommendation is to use insulin as the initial ... Related articles - All 5 versions
JM Gamble, SH Simpson, LC Brown, JA … - Open Medicine, 2008 - openmedicine.ca Data sources: We searched the following electronic databases from inception
until June 2007: MEDLINE; EMBASE; Cochrane Central Register of Controlled
Trials; Web of Science; Scopus; CINAHL; International Pharmaceutical ... Related articles - Cached - All 2 versions
